3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Papillomavirus Infections
1
Neoplasms
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Leukoplakia
1
Leukokeratosis, Hereditary Mucosal
1
Glioma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
49
Specimen Handling
29
Magnetic Resonance Spectroscopy
25
Biopsy
25
Radiosurgery
17
Gemcitabine
17
Nivolumab
16
Cyclophosphamide
14
Cisplatin
14
Paclitaxel
13
Carboplatin
13
Bevacizumab
13
Leucovorin
11
Irinotecan
11
Fluorouracil
11
Drug Therapy
11
Taxes
10
Radiotherapy
10
Oxaliplatin
10
Capecitabine
10
trastuzumab deruxtecan
9
fludarabine
9
cemiplimab
8
Doxorubicin
8
Cetuximab
8
abemaciclib
7
Trastuzumab
7
Pemetrexed
7
Fulvestrant
7
Docetaxel
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm Metastasis
×
Imiquimod
×
Clear all
NCT06686043
2024-11-13
HPV-VIM
Baylor College of Medicine
Phase 2
Recruiting
85 enrolled